Loading…
Kairos Pharma, Ltd. is projected to decline to $0.4592 by 2027, a -11% move from its current price of $0.5172. KAPA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.4994 | $0.5172 | $0.5356 | 0.00% |
| May 30 | $0.4923 | $0.5172 | $0.5435 | +0.01% |
| May 31 | $0.4868 | $0.5173 | $0.5496 | +0.01% |
| Jun 1 | $0.4823 | $0.5173 | $0.5548 | +0.02% |
| Jun 2 | $0.4784 | $0.5173 | $0.5594 | +0.02% |
| Jun 3 | $0.4748 | $0.5173 | $0.5636 | +0.03% |
| Jun 4 | $0.4716 | $0.5174 | $0.5675 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4716 | $0.5174 | $0.5675 | +0.03% |
| Week 2 | $0.454 | $0.5175 | $0.5899 | +0.06% |
| Week 3 | $0.441 | $0.5177 | $0.6077 | +0.09% |
| Week 4 | $0.4303 | $0.5178 | $0.6231 | +0.12% |
| Week 5 | $0.4211 | $0.518 | $0.6371 | +0.15% |
| Week 6 | $0.413 | $0.5181 | $0.65 | +0.18% |
| Week 7 | $0.4057 | $0.5183 | $0.6621 | +0.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on cancer immunotherapy and cell therapies. It develops therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
ENV 105 is an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company’s preclinical programs include KROS 201 that activates T cells using dendritic cells, KROS 101, an orally available GITR ligand small-molecule antagonist, KROS 102, a GITR antagonist, KROS 301, a tumor-targeting small molecule and checkpoint inhibitor, KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc.
and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Kairos Pharma, Ltd. (KAPA) operates in the healthcare sector as a clinical-stage biopharmaceutical company focused on cancer immunotherapy and cell therapies. The stock is currently priced at $0.545, with a market cap of $11.67M and a market rank of 5113.
The current price and market position place it in a highly selective segment of small-cap healthcare equities. The long-range forecast shows a mixed near-term path with a potential for meaningful upside later, including bullish opportunities beginning in 2031 and extending through 2050.
A major floor 35.4% below — a decisive break under it would weaken the trend.
The nearest floor, 10.3% below — buyers have tended to step in here.
The nearest ceiling, 32.4% above — a clean break opens room to run.
A major ceiling 69.2% above — clearing it would confirm fresh momentum.
Key KAPA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KAPA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.529 | Sell | $0.5204 | Sell |
| MA 10 | $0.5041 | Buy | $0.5193 | Sell |
| MA 20 | $0.5264 | Sell | $0.5317 | Sell |
| MA 50 | $0.5721 | Sell | $0.5696 | Sell |
| MA 100 | $0.6295 | Sell | $0.6382 | Sell |
| MA 200 | $0.856 | Sell | $0.7769 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.53 | Neutral |
| Stoch RSI (14) | 71.70 | Neutral |
| CCI (20) | -20.24 | Neutral |
| Williams %R (14) | -44.79 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -7.68 | Sell |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 55.21 | Neutral |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 55.17 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 0.54 | Sell |
| ADX (14) | 18.40 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is neutral. The RSI(14) sits at 50, with the 50-day simple moving average at $0.5757 and the 200-day simple moving average at $0.8605. Support is identified at $0.464 and resistance at $0.685, with the 30-day price range spanning from $0.4303 to $0.6903.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.464 | $0.5172 | $0.6954 | 0% | Neutral | |
| $0.3542 | $0.4592 | $0.636 | -11% | Neutral | |
| $0.3609 | $0.4849 | $0.7019 | -6% | Neutral | |
| $0.356 | $0.4931 | $0.7388 | -5% | Neutral | |
| $0.3378 | $0.4806 | $0.7413 | -7% | Neutral | |
| $0.4221 | $0.6158 | $0.9741 | +19% | Neutral | |
| $0.4407 | $0.6581 | $1.06 | +27% | Bullish | |
| $0.4096 | $0.6255 | $1.03 | +21% | Bullish | |
| $0.404 | $0.6301 | $1.06 | +22% | Bullish | |
| $0.3692 | $0.5875 | $1.01 | +14% | Neutral | |
| $0.5044 | $0.882 | $1.62 | +71% | Bullish | |
| $0.6257 | $1.30 | $2.65 | +150% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.464 | $0.5172 | $0.6084 | +0.00% |
| June 2026 | $0.4284 | $0.5063 | $0.6147 | -2.12% |
| July 2026 | $0.4346 | $0.5192 | $0.6412 | +2.55% |
| August 2026 | $0.4518 | $0.5443 | $0.6811 | +4.84% |
| September 2026 | $0.4433 | $0.5379 | $0.6802 | -1.18% |
| October 2026 | $0.4281 | $0.5227 | $0.6674 | -2.82% |
| November 2026 | $0.4338 | $0.5328 | $0.686 | +1.93% |
| December 2026 | $0.4339 | $0.5358 | $0.6954 | +0.57% |
Click any year to see its month-by-month KAPA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Kairos Pharma, Ltd.'s 2026 outlook centres on $0.5172, within a $0.464 to $0.6954 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, KAPA could reach as high as $0.636, with a base case around $0.4592 and support toward $0.3542 — roughly -11% from $0.5172. A consolidation phase looks the most probable path here.
Expect KAPA to range from $0.3609 to $0.7019 through 2028. The $0.4849 average target implies a -6% move from current prices. That is up +6% on the projected 2027 average. Price action looks broadly range-bound.
The KAPA price prediction for 2029 points to an average of $0.4931 (low $0.356, high $0.7388) — a potential decline of -5% on today's $0.5172. A consolidation phase looks the most probable path here.
In 2030, KAPA is projected to trade between $0.3378 and $0.7413, averaging $0.4806 — a potential decline of -7% from today's $0.5172. That is -3% versus the projected 2029 average. Price action looks broadly range-bound.
Kairos Pharma, Ltd.'s 2031 outlook centres on $0.6158, within a $0.4221 to $0.9741 range. That is up +28% on the projected 2030 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, KAPA could reach as high as $1.06, with a base case around $0.6581 and support toward $0.4407 — roughly +27% from $0.5172. Momentum favours further upside here.
Expect KAPA to range from $0.4096 to $1.03 through 2033. The $0.6255 average target implies a +21% move from current prices. That is -5% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The KAPA price prediction for 2034 points to an average of $0.6301 (low $0.404, high $1.06) — a potential gain of +22% on today's $0.5172. Momentum favours further upside here.
In 2035, KAPA is projected to trade between $0.3692 and $1.01, averaging $0.5875 — a potential gain of +14% from today's $0.5172. That is -7% versus the projected 2034 average. A consolidation phase looks the most probable path here.
Kairos Pharma, Ltd.'s 2040 outlook centres on $0.882, within a $0.5044 to $1.62 range. That is up +50% on the projected 2035 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2050, KAPA could reach as high as $2.65, with a base case around $1.30 and support toward $0.6257 — roughly +150% from $0.5172. Buyers look set to stay in control over this stretch.
Investing $1,000 in KAPA today (≈ 1,933.488012 KAPA) could be worth
$2,504.74
+$1,504.74 (+150%) by 2050 · US Dollar
Based on the average projected KAPA price of $1.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KAPAwould be worth at today's price.
$1,000 invested in KAPA on May 27, 2025 (≈ 1,564.94523 KAPA) would be worth
$809.39
-$190.61 (-19.1%) today · 0.81× · US Dollar
Based on a KAPA entry price of $0.639 vs. today's $0.5172.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.513 | $1,008.19 | +0.8% |
| 1 month ago | $0.599 | $863.44 | -13.7% |
| 3 months ago | $0.552 | $936.96 | -6.3% |
| 6 months ago | $0.834 | $620.14 | -38.0% |
| 1 year ago | $0.639 | $809.39 | -19.1% |
| All time (1.7y) ago | $2.6 | $198.92 | -80.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KAPA forecast.
Our base-case forecast reaches $1.00 around 2050.
Implied market cap at $1.00: $21.41M
The year-by-year forecast shows muted near-term dynamics through 2030, with average prices around the mid-$0.5s and neutral sentiment: 2026 (avg $0.545, ROI 0%), 2027 (avg $0.4825, ROI -11.5%), 2028 (avg $0.517, ROI -5.1%), 2029 (avg $0.5254, ROI -3.6%), and 2030 (avg $0.5212, ROI -4.4%). Beginning in 2031 the outlook turns bullish, with 2031 avg $0.6746 (ROI 23.8%), 2032 avg $0.7077 (ROI 29.9%), 2033 avg $0.6661 (ROI 22.2%), and 2034 avg $0.6793 (ROI 24.6%), followed by 2035 avg $0.6279 (ROI 15.2%, neutral). The forecast continues with strong upside in 2040 (avg $0.9626, ROI 76.6%, bullish) and 2050 (avg $1.40, ROI 157.8%, bullish).
These are estimates and not guarantees; actual results depend on market conditions and clinical progress.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.5212 with a minimum of $0.364 and a maximum of $0.8091; the projected ROI is -4.4% and sentiment is NEUTRAL.
Near-term sentiment remains NEUTRAL through 2030 with some negative ROIs, but the forecast turns BULLISH from 2031 onward (2031–2034 average values ~ $0.6746–$0.6793 with ROIs of 22.2–29.9). This indicates potential upside over the longer term but carries substantial risk.
Yes, the forecast shows higher potential values in later years, with the 2040 max at $1.79 and the 2050 max at $2.90, suggesting a path above $1 in the coming decades.
The current price is $0.545 and the market capitalization is $11.67M.
2031: avg $0.6746, max $1.07, min $0.4592, ROI 23.8, sentiment BULLISH. 2032: avg $0.7077, max $1.15, min $0.4702, ROI 29.9, BULLISH. 2033: avg $0.6661, max $1.11, min $0.4326, ROI 22.2, BULLISH. 2034: avg $0.6793, max $1.15, min $0.4316, ROI 24.6, BULLISH.
Kairos Pharma, Ltd. Community Discussion
0Share your Kairos Pharma, Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.